IQV vs ZBH
IQVIA vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | IQV | ZBH |
|---|
| AI Score |
70
|
69
|
| Price |
$236.69
|
$100.62
|
| P/E Ratio |
29.11×
|
24.37×
|
| ROE |
20.9%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
26.2%
|
69.9%
|
| Debt / Equity |
2.63×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
64.6
|
68.8
|
| Beta |
1.175
|
0.462
|
| Expected Upside |
+4.2%
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for IQV versus ZBH.
IQV leads by 1 points.
IQV scores 70/100 (Buy) versus ZBH at 69/100 (Buy).
IQV Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 30.0% signals elevated volatility — Risk
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical